These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 26409344)

  • 41. EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease.
    Berardelli A; Wenning GK; Antonini A; Berg D; Bloem BR; Bonifati V; Brooks D; Burn DJ; Colosimo C; Fanciulli A; Ferreira J; Gasser T; Grandas F; Kanovsky P; Kostic V; Kulisevsky J; Oertel W; Poewe W; Reese JP; Relja M; Ruzicka E; Schrag A; Seppi K; Taba P; Vidailhet M
    Eur J Neurol; 2013 Jan; 20(1):16-34. PubMed ID: 23279440
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structural connectivity in Parkinson's disease.
    Tessitore A; Giordano A; Russo A; Tedeschi G
    Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1():S56-9. PubMed ID: 26394678
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of biomarkers and imaging in Parkinson's disease.
    Algarni MA; Stoessl AJ
    Expert Rev Neurother; 2016; 16(2):187-203. PubMed ID: 26829357
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neuroimaging in Parkinson's disease: from pathology to diagnosis.
    Stoessl AJ
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S55-9. PubMed ID: 22166455
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neuroimaging in Parkinson's disease.
    Stoessl AJ
    Neurotherapeutics; 2011 Jan; 8(1):72-81. PubMed ID: 21274687
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Functional imaging in Parkinson's disease.
    Dagher A
    Semin Neurol; 2001; 21(1):23-32. PubMed ID: 11346022
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of neuroimaging in the diagnosis of the atypical parkinsonian syndromes in clinical practice.
    Dąbrowska M; Schinwelski M; Sitek EJ; Muraszko-Klaudel A; Brockhuis B; Jamrozik Z; Sławek J
    Neurol Neurochir Pol; 2015; 49(6):421-31. PubMed ID: 26652877
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Changes of brain structural network connection in Parkinson's disease patients with mild cognitive dysfunction: a study based on diffusion tensor imaging.
    Wang W; Mei M; Gao Y; Huang B; Qiu Y; Zhang Y; Wang L; Zhao J; Huang Z; Wang L; Nie K
    J Neurol; 2020 Apr; 267(4):933-943. PubMed ID: 31792673
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Imaging analysis of Parkinson's disease patients using SPECT and tractography.
    Son SJ; Kim M; Park H
    Sci Rep; 2016 Nov; 6():38070. PubMed ID: 27901100
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The contribution of neuroimaging for the study of cognitive deficits in Parkinson's disease.
    Monchi O; Martinu K; Strafella AP
    Clin EEG Neurosci; 2010 Apr; 41(2):76-81. PubMed ID: 20521489
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Innovative MRI techniques in Parkinson's disease].
    Baudrexel S; Klein JC; Deichmann R; Hilker R
    Nervenarzt; 2010 Oct; 81(10):1180-8. PubMed ID: 20798918
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Role of Neuroimaging in the Diagnosis and Treatment of Depressive Disorder: A Recent Review.
    Song T; Han X; Du L; Che J; Liu J; Shi S; Fu C; Gao W; Lu J; Ma G
    Curr Pharm Des; 2018; 24(22):2515-2523. PubMed ID: 30051778
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The predictive value of transcranial sonography in clinically diagnosed patients with early stage Parkinson's disease: comparison with DAT PET scans.
    Liu P; Li X; Li FF; Ou-Yang QH; Zhang HX; Feng T
    Neurosci Lett; 2014 Oct; 582():99-103. PubMed ID: 25218716
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biomarkers in Parkinson's disease (recent update).
    Sharma S; Moon CS; Khogali A; Haidous A; Chabenne A; Ojo C; Jelebinkov M; Kurdi Y; Ebadi M
    Neurochem Int; 2013 Sep; 63(3):201-29. PubMed ID: 23791710
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Imaging of Motor Cortex Physiology in Parkinson's Disease.
    Burciu RG; Vaillancourt DE
    Mov Disord; 2018 Nov; 33(11):1688-1699. PubMed ID: 30280416
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The sensitivity of 18-fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease.
    Heiss WD; Hilker R
    Eur J Neurol; 2004 Jan; 11(1):5-12. PubMed ID: 14692881
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Functional neuroimaging in Parkinson's disease.
    Niethammer M; Feigin A; Eidelberg D
    Cold Spring Harb Perspect Med; 2012 May; 2(5):a009274. PubMed ID: 22553499
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Incentive-driven decision-making networks in de novo and drug-treated Parkinson's disease patients with impulsive-compulsive behaviors: A systematic review of neuroimaging studies.
    Martini A; Tamburin S; Biundo R; Weis L; Antonini A; Pizzolo C; Leoni G; Chimenton S; Edelstyn NMJ
    Parkinsonism Relat Disord; 2020 Sep; 78():165-177. PubMed ID: 32927414
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multimodal imaging reveals a complex pattern of dysfunction in corticolimbic pathways in major depressive disorder.
    Nugent AC; Farmer C; Evans JW; Snider SL; Banerjee D; Zarate CA
    Hum Brain Mapp; 2019 Sep; 40(13):3940-3950. PubMed ID: 31179620
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sex effects on brain structure in de novo Parkinson's disease: a multimodal neuroimaging study.
    Tremblay C; Abbasi N; Zeighami Y; Yau Y; Dadar M; Rahayel S; Dagher A
    Brain; 2020 Oct; 143(10):3052-3066. PubMed ID: 32980872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.